Genfit assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Genfit (GNFT) with a Buy rating and $9 price target The company is developing therapies for rare and severe liver diseases, with a focus on acute-on-chronic liver failure, the analyst tells investors in a research note. The firm says the company is expected to readout multiple meaningful clinical updates in 2025 and beyond, providing a number of catalysts for the shares.